Loading...
•
Sep 30, 2023
Scorpius Holdings Q3 2023 Earnings Report
NightHawk Biosciences' Q3 2023 strategic, financial, and operational updates were provided.
Key Takeaways
NightHawk Biosciences reported $0.6 million in revenue from process development and $0.1 million from service revenue for the third quarter of 2023. The company had approximately $9.5 million in cash, cash equivalents, and short-term investments as of September 30, 2023.
Recognized $0.6 million in revenue from process development.
Recognized $0.1 million from service revenue.
Research and development expenses decreased by approximately 3.7% to $5.2 million.
As of September 30, 2023, the Company had approximately $9.5 million in cash, cash equivalents, and short-term investments.
Forward Guidance
The company is evaluating strategic options to maximize the potential of the Scorpius San Antonio facility, and will provide updates in the near future.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...